The New England journal of medicine

• Latest
• Best
• Search…

• N. Engl. J. Med. · Aug 2023

  Case Reports

  Serum Sickness.

  no abstract available

  explore further… or just mark as read…

• N. Engl. J. Med. · Aug 2023

  Comment Letter

  Medical and Public Health Imperatives of Xylazine. Reply.

  no abstract available

  expand abstract… mark as read…

• N. Engl. J. Med. · Aug 2023

  Letter

  Cell-of-Origin Subtypes and Therapeutic Benefit from Polatuzumab Vedotin.

  no abstract available

  read more… or not…

• N. Engl. J. Med. · Aug 2023

  Editorial

  Improving Dialysis Techniques for Patients?

  no abstract available

  read more… or not…

• N. Engl. J. Med. · Aug 2023

  Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation.

  Divarasib (GDC-6036) is a covalent KRAS G12C inhibitor that was designed to have high potency and selectivity. ⋯ Treatment with divarasib resulted in durable clinical responses across KRAS G12C-positive tumors, with mostly low-grade adverse events. (Funded by Genentech; ClinicalTrials.gov number, NCT04449874.).

  read more… or just mark as read…